51 – In-Depth Analysis of FDA cGCP Regulations (S21E2)

You know, it's funny, we put so much trust in
the medicines we take, right? We expect them
to be safe. We expect them to work. But have
you ever really thought about all that goes into
actually making sure that's true, especially
when we're talking about brand new drugs still
in clinical trials? I mean, the whole system,
it's massive. It's intricate. It's a bit mind
-boggling when you really dive in. Yeah, absolutely.
And I think that's what we're going to try to
do today. We're going to demystify some of these
regulations, these really important processes
that are in place. Specifically, we're taking
a deep dive into the FDA's current good clinical
practice regulations, CGCP for short, here in
the US. And for everyone listening, we really
want to give you a solid understanding of all
the details, the guidelines that govern these
clinical trials. We'll be breaking down how the
FDA guidance documents, those key sections of
Title 21 of the Code of Federal Regulations,
we call it 21 CFR for short, and all those helpful
question and answer documents they put out all
work together to shape clinical trials as they're
happening today. Think of it like this. We're
giving you a clear path to being well -informed,
but without getting lost in the weeds of the
tech. stuff. Exactly. And to do that, we've pulled
together a bunch of resources. We're going to
be looking at official guidance documents from
the FDA, examining the relevant sections of 21
CFR, going through some of those really helpful
Q &A documents, and even picking out insights
from transcripts of actual FDA training sessions.
So much good stuff. All right, let's get into
it. To really understand where we are with CGCP
today, it helps to take a quick look back. How
did drug regulation even evolve in the US? Because
believe it or not, there was a time when things
were, well, let's just say, quite different from
how we handle things now. What's fascinating
to me is how certain public health events, these
big moments in history, really pushed the need
for these changes, like the 1906 Pure Food and
Drug Act. What was the main goal of that? Do
you remember? Well, from what I recall, that
act was all about stopping the interstate sale
of any food or drugs that were mislabeled, you
know, or if they had harmful ingredients. It
was a step in the right direction, for sure,
acknowledging that we needed some oversight,
but it didn't solve everything. There were still
some pretty questionable things that could end
up in medicines back then. Exactly. And then
unfortunately, we had that terrible incident
in 1937 with the sulfanolamide elixir. They used
diethylene glycol as the solvent. And if you
don't know, that's basically antifreeze. Just
awful. Led to over 100 deaths. In that event,
that was a major push behind the 1938 Food, Drug,
and Cosmetic Act. What would you say was the
biggest change that this act brought in? That
act, it brought in mandatory pre -market safety
testing for new drugs. So for the first time
ever, drug companies actually had to prove their
products were safe for people before they could
sell them. But even then, they didn't have to
prove the drug actually worked. You know, it's
efficacy that wasn't a legal requirement yet.
Right. And then fast forward to the early 60s,
we had the thalidomide tragedy. I mean, heartbreaking.
Thalidomide, it was a sedative, but it caused
terrible birth defects in thousands of babies
in Europe. Thankfully, it wasn't widely approved
here in the US. Dr. Frances Kelsey at the FDA,
she really deserves credit for that. But still,
it exposed a big problem. How did regulations
respond to this crisis? That's when we got the
1962 Kefau -Harris amendments. And let me tell
you, those were a game changer. Not only do they
keep the safety testing, but now companies had
to prove their drug was actually effective for
its intended use. They had to show real evidence
that their drugs did what they claimed. So we
went from just making sure things weren't outright
dangerous or mislabeled to proving they were
safe. And finally, to proving they were both
safe and effective. It's pretty incredible when
you lay it out like that. Each step, a direct
response to a major public health crisis. It's
like this clear line of progress, right? Back
before 1906, clinical trials, they weren't even
standard practice. Dangerous ingredients could
slip into medicines. But look at us now, we have
this comprehensive system. All those advancements
in regulation, they were all about protecting
public health. And that leads us right to where
we are now, with this strong emphasis on good
clinical practice. Makes you appreciate how far
we've come. It really does. OK, so we've seen
how drug regulation has changed over time. And
it's clear that making sure these new drugs being
tested in clinical trials are safe and effective
is, I mean, it's vital. But it's not just about
the trials themselves, right? It's also about
how those drugs, those investigational products
are actually made in the first place. That's
where GMP comes in. And that connection between
CGCP. which is all about running the trials properly,
and GMP, which stands for Good Manufacturing
Practice. That's so important. GMP regulations,
like those outlined in 21 CFR Part 211, they
guarantee the quality of those investigational
products being used in the trials. It's not enough
to just do the trial right. The drug itself has
to be made to a high standard consistently. Think
about it. If the drug's flawed or it varies from
batch to batch, how can you trust the results
of the trial? Absolutely. Whether it's a pill,
an injection, whatever form it takes, that investigational
drug has to be produced at a high level of quality
every single time. And I remember our sources
mentioned that GMP training often focuses on
five main elements. What are those again? Let's
see. Those five key elements are people, premises,
processes, products, and procedures. You need
well -trained people working in the right facilities,
following clear processes to create consistent
products, and all of that according to established
procedures. Just imagine, if the people making
the drug aren't properly trained, it could directly
affect how good that drug is, how consistent
it is, and that could totally mess up the trial
results. Makes total sense. It's about making
sure quality is built in from the very beginning
throughout the entire process of making that
drug. not just when it gets to the clinical trial.
Exactly. That's the foundation. And it's absolutely
crucial to the reliability of the clinical trial
results. If the investigational product itself
is all over the place, how can you really know
if it's safe and if it actually works? OK. So
let's talk about actually testing a new drug
in people. We know you can't just start giving
it to participants without some oversight from
the FDA, right? And that's where the Investigational
New Drug Application, or IND, comes into play.
You got it. And 21 CFR Part 312, that's part
of the regulations all about INDs. It says most
studies involving new drugs need to be done under
an IND. What would you say is the main purpose
of this application? Well, the IND, it's like
the sponsors, usually the drug company formal
way of giving all the necessary information to
the FDA. This lets the FDA make sure of a few
really important things. First off, the safety
and the rights of the people participating in
the trial. Second, the quality of the drug itself.
And third, that the whole study is designed well
enough to actually evaluate if the drug is safe
and effective for what it's supposed to be used
for. And the FDA, they have a limited time to
review it once they get that initial IND protocol
right. How long do they have, and what can they
do during that time? They have 30 days to review
that initial submission. During that time, they're
looking at the study design, all the data supporting
it, all the details. And if something's not right,
like maybe they have concerns about the safety
of the protocol or the way the drug is being
manufactured, they can issue what's called a
clinical hold. And it's important to note that
there are different types of clinical holds.
What's the difference between them? Right, so
there's a full clinical hold, which means everything
stops, no new participants can be enrolled, and
usually anyone already in the study has to stop
taking the drug. But then there's also a partial
clinical hold. That might happen if the FDA is
only concerned about a specific part of the study,
maybe a certain dosage level, but not the whole
design. So the hold only applies to that part.
Let's say they were worried about a really high
dose being tested. They might just put a partial
hold on that part of the study, but other parts
could continue. Interesting. Now, I know there
are some exceptions to needing an IND. Not every
study involving a drug needs one. What are some
of those cases? There are a few key ones, like
if the drug is already legally sold in the US
for specific use, or if the study isn't meant
to support a new use for the drug or a big change
to its label, and also if the study doesn't significantly
increase the risk to the participants. But, and
this is important, Even if a study doesn't need
an IND, it still has to follow all the other
regulations. You know, the ones about institutional
review boards, IRBs, getting informed consent
from participants, and the rules about promoting
the drug. So even if a study doesn't need that
formal IND oversight, those basic principles
of keeping participants safe, that always comes
first. Absolutely. And when a clinical trial
is all set to go, there's one person who has
a huge responsibility. The clinical investigator.
And there's that formal agreement between the
investigator and the sponsor, all laid out on
the FDA Form 1572. Can you tell me more about
this form? Why is it so important? It's really
simple. Investigators can't legally participate
in a clinical trial unless they've given the
sponsor a signed 1572 form. And section nine
of that form, that's where it gets interesting.
It lists eight commitments the investigator agrees
to. It's basically the FDA saying, here's what
we expect from anyone running clinical research.
So what are some of the commitments the investigator
makes when they sign that form? Well, the biggest
one is that they'll do the entire investigation
exactly according to the plan, the protocol,
and they won't change anything without the sponsor
agreeing and the IRB approving it unless it's
an emergency, you know, to protect the safety
of a participant. They also promise to make sure
every potential participant understands what
they're getting into and gives their informed
consent. And that has to be done according to
21 CFR Part 50, which is all about informed consent.
Another big one is making sure the study has
been reviewed and approved by an insta - Review
Board, the IRB, they're the ones protecting the
rights of the people in the research. And of
course they agree to keep accurate records, everything
documented properly. And probably one of the
most important parts is the overall responsibility
of the clinical investigator. Can you talk more
about that? The investigator, they're ultimately
responsible for how the whole trial is conducted
at their site. They have to supervise everyone
they delegate tasks to, their research team,
any outside help they bring in. Even if someone
else is doing a specific task, the investigator
is still accountable. Did the trial follow the
rules? Is the data good? Are the participants
safe? It all comes back to them. That's why it's
so important for investigators to have the right
resources, the right training, and to really
focus on the most critical parts of the trial,
the areas where things could go wrong. So even
though the investigator can delegate tasks, They
can't delegate that final responsibility. They're
the ones who have to make sure everything is
done ethically and scientifically. Exactly. And
speaking of doing things right, that brings us
to a really important principle, something that's
fundamental to GMP and good clinical practice,
good documentation practices, GDP. One of our
sources put it perfectly. If it wasn't documented,
it didn't happen. Why is documentation so important
in this whole world of regulations? Good documentation
practices, they're the key to being able to trace
everything back, to know who did what and when.
It all comes down to quality and integrity for
every single step. Whether we're talking about
making the drug or running the trial, if something
wasn't documented, you just can't prove it happened.
Was it done right? Was it done at the right time
by the right person? You just don't know. Accurate
records made at the time things happen, that's
the proof that procedures were followed, that
the data is reliable. In our sources, they actually
had a whole video transcript about applying GDP.
They highlighted some really practical guidelines.
Let's walk through some of those. What are some
of the basic rules for writing in official records,
for example? Okay, so rule number one, use indelible
ink. No pencils, no erasable ink, you don't want
anyone changing things later on. Then most companies
will have standard operating procedures, SOPs,
that tell you exactly how to write your signature
and initials. You gotta stick to those rules.
And it's usually a good idea to keep a signature
log book, you know, for everyone involved in
GMP stuff, employees, part -timers, even consultants.
That way you can always check if the signature
is legit. And what about when you should make
entries, and how do you deal with blank space?
on a record. You should make entries as things
happen, real time or as soon as you can afterwards.
You can't do something on the manufacturing floor
and then go back to your office hours later and
fill out the paperwork. And never leave blank
spaces. If something doesn't apply, write NA
for not applicable or draw a line through it
and initial and date it. That way no one can
sneak in extra information later that wasn't
there originally. What about using computers
or things like sticky notes when we're talking
about GMP? For official GMP records, you generally
can't use things like electronic sticky notes.
Those temporary annotations, they're not considered
a real part of the record. And for paper records,
never use actual sticky notes as a permanent
thing. When you make copies, they have to be
clear, easy to read, no mistakes. And if it's
more than one page, use page numbers, like page
one of three, you know, to make sure you have
all the pages. And this is a big one. Never,
ever get rid of original pages from an official
GMP document. I see. And a signature, it can
mean different things depending on what you're
looking at. What are some of the ways a signature
is used in GMP documentation? A signature can
show a few things. It can mean the person who
signed actually did the thing being documented,
or it can mean they're writing down what someone
else saw or told them, like if someone working
in a clean room couldn't write it themselves.
And it can also mean the person is verifying
that something was done right, that the record
is accurate. But remember, you can never verify
your own work. Someone else who knows what they're
doing has to do it. Someone who ideally saw you
do it right in the first place. So good documentation
practices, they're about creating a clear record,
something you can check every action, every observation,
every decision throughout the entire process
of making and testing a drug. That's how you
ensure the data is good and lets you go back
and see exactly what happened if you need to.
Exactly. And that same attention to detail, that
rigor, it goes beyond paperwork. It extends to
the actual lab testing of those drugs. That's
where laboratory controls come in. In laboratory
controls, they're a crucial part of GMP, especially
when we're talking about dietary supplements.
I was reading the EAS consulting group transcript
about 21 CFR Part 111. That's the one specifically
for dietary supplements. And they really highlighted
that. So what are some of the main things a quality
control lab does in that context? The QC lab,
they have a ton of responsibility. They're doing
analytical testing to figure out what's in the
raw materials, the finished products, even samples
taken during manufacturing. They're checking
for purity, potency, all those things. They're
also doing microbiological testing, making sure
there are no nasty bugs in there, and physical
testing, checking the appearance, how it breaks
down, all that. Plus, they're often involved
in developing and validating the actual testing
methods themselves. Got to make sure those are
reliable. And sometimes they even manage stability
testing, seeing how the product's quality holds
up over time in different conditions and you
know it's interesting the FDA they often find
problems with how companies set product specifications
that's 21 CFR 111 .70 and with the actual testing
itself 21 CFR 111 .75 so those are clearly areas
they focus on when it comes to dietary supplements.
Now for a testing method to be considered scientifically
sound to be reliable enough for a QC lab to use
it needs to have some specific qualities. What
are those? A good testing method has to be accurate.
The results it gives should be close to the true
value of what you're measuring. They often test
this by spiking samples with a known amount of
the thing they're looking for. And it has to
be precise, meaning if you test the same sample
a bunch of times, you should get similar results
each time. Specificity is important, too. The
method has to be able to measure what you're
interested in without being thrown off by other
stuff in the sample. Then there's ruggedness.
That means the method still works, even if little
things change, like different people doing the
test, different equipment, different days. And
finally, every method needs a clear purpose.
What is it supposed to measure? How will the
results be used? You have to define all that.
And there are some established resources that
provide these validated test methods, methods
that labs can use. What are some of those? Some
of the big ones are the United States Pharmacopeia,
the USP. They have standards for drugs and supplements.
Then you've got AOAC International. They develop
and validate methods, too. The Food Chemicals
Codex, FCC, they provide quality standards for
food ingredients. For microbiology, the FDA's
bacteriological analytical manual, BAM, is really
important. And for For environmental testing,
sometimes they use methods from the Environmental
Protection Agency, the ETA. And just like with
manufacturing, good documentation is super important
in the lab. What are the rules about documenting
lab work? Everything you do in the lab has to
be documented, no exceptions, doesn't matter
if it's on paper or in a computer system, and
you have to do it as you're doing the work. That's
something they really stress in the GMP regulations.
The documentation needs to be detailed enough
that you could basically recreate the whole experiment
just by reading it, but it should also be clear
and easy to understand. And all those good documentation
practices we talked about earlier, those still
apply. Invaluable ink, proper signatures, no
blank spaces, all that. I see. And 21 CFR Part
212, that has some extra requirements for the
testing methods used in non -clinical lab studies.
What are some of those? Part 212 says that those
lab methods have to be suitable for what they're
being used for. They have to be sensitive enough
to detect what you're looking for, specific enough
to target the right thing, and accurate and reproducible,
meaning you get consistent results. And all the
stuff used for testing, like reagents, standards,
solutions, those all have to be controlled and
labeled properly. you need to know what it is
and when it expires. And who's usually responsible
for creating and approving things like the specifications
for raw materials and finished products and the
actual procedures for testing them in the QC
lab. Usually the technical folks in the company,
often the QC lab itself, they're the ones who
come up with those specifications for the materials
and the products, and they develop the sampling
plans and test procedures. But then, the quality
control unit has to review and approve all of
that to make sure it meets the standards. And
if you ever have to deviate from those written
procedures, you have to document it, explain
why, and get it approved. And of course, all
the test results and conclusions have to be documented
too. Plus, you have to keep good inventory records
and make sure everything adds up, no ingredients
going missing. So it's clear that from the time
the raw materials arrive at the facility, to
when that finished drug is ready for clinical
trials, there are a ton of controls in place.
Not just for making and testing the drug, but
also for the materials and equipment used along
the way. Absolutely. It's all about controlling
the environment in a pharmaceutical facility.
You have to prevent contamination, make sure
that product is high quality. our source on good
design practices for GMP pharmaceutical facilities,
they emphasize how important it is to separate
different manufacturing areas. How do they usually
do that? They control the flow of people. materials
and equipment very carefully. Different areas
will have different classifications depending
on how clean they need to be, and you can't just
go from one to the other freely. They use airlocks,
those little rooms with interlocking doors, to
create a transition zone between areas with different
cleanliness levels. That prevents air and any
contaminants in it from flowing directly between
areas. And they use these detailed diagrams to
show people the right way to move through the
facility, how to put on gowns, which hallways
to use, how to move materials through special
chambers. It's all very controlled. Makes sense.
And beyond the physical layout, what are the
rules about keeping equipment clean and preventing
contamination? 21 CFR Part 110. That's the one
about good manufacturing practices for food,
but it also has principles that apply to drugs.
It says you have to keep all the equipment and
utensils clean and sanitary. They have to be
cleaned and sanitized regularly, and that often
means taking them apart to make sure you get
every surface. And the whole manufacturing package
and storage process has to be done in a way that
minimizes contamination, whether it's a bacteria
or other stuff getting in. This means monitoring
things like temperature and humidity and having
strict controls to prevent contaminants from
being introduced and spreading. And what about
the raw materials themselves and the finished
drug products? What are the requirements there?
Raw materials, whether they're liquid or dry,
have to be protected from contamination. And
21 CFR Part 111, that's the one about dietary
supplements. But again, it has good general GMP
principles. It says you need written procedures
for everything. Manufacturing, packaging, labeling,
the whole process. And before you can use any
component, whether it's a container, a closure,
anything, you have to test it according to the
specifications and either approve it or reject
it. That's 21 CFR 211 .84. So you're only using
stuff that meets the quality standards. In all
of this, all these processes, it creates a lot
of data, a lot of paperwork. How do they manage
all those records? What does the FDA expect?
Record keeping is a huge deal in GMP. 21 CFR
Part 211, specifically subparts G, J, K, and
P, those lay out all the details about production
and control records, including packaging and
labeling. And here's the kicker, those records
have to be reviewed and approved by the quality
control unit before you can release a single
batch of the drug. They're making sure everything
was done right and the final product meets all
the standards. And what happens if something
goes wrong with a batch? What if it doesn't meet
the specifications? If something's off, like
maybe the yield is wrong or the batch fails a
test, you have to investigate right away. And
it's not just about that one batch. You have
to look at other batches of the same drug, maybe
even other products made using the same equipment,
just in case. And you have to document the whole
investigation. What happened? What did you do?
What did you find out? What are you going to
do to fix it and prevent it from happening again?
That's all documented. And 21 CFR 211 .194 that
specifically says you need detailed lab records
for all the tests and examinations you do. And
you also need a way to go back and check a batch
even after it's been sold. What are the rules
about keeping reserve samples? That's right.
The regulations say you have to keep reserved
samples of every batch and you have to store
them properly, even after you've sold the last
of that drug with that specific active ingredient.
For most drugs, you have to keep those samples
for at least a year after the expiration date,
or three years after it was sold if there's no
expiration date. And those samples have to be
in the same container the product is sold in,
and you need enough to do all the tests on it.
Except for sterility and pyrogen testing. So
we've talked about developing the drug, making
it, testing it, and all that documentation, but
how does the FDA actually make sure companies
are following all these rules? That's where inspections
and enforcement actions come in. And that's where
the FDA's bio -research monitoring program comes
into play. They do on -site inspections and data
audits of clinical trials. We learned about that
in the FDA CITC 2024 Day 3 transcript. What's
the main purpose of those inspections? Those
inspections, they're all about seeing what's
really happening at those clinical trial sites
and within the sponsor companies. The FDA wants
to know if the way things are being done could
affect the data, the results of the trial, and
they also want to make sure the participants
are safe and their rights are being protected.
And it's interesting, the FDA... They're pretty
adaptable. They change their inspection methods
to fit different types of clinical trials, even
the new and innovative ones. And who are the
people doing these inspections? Do they usually
interact directly with the sponsor? It's usually
FDA investigators, and they're often organized
by region. But for trials outside the US, sometimes
it's just one investigator handling it. Now,
as for the sponsor being there during an inspection
of a clinical investigator site, the FDA doesn't
have a rule about it one way or the other. But
usually, the sponsor isn't there. And if the
FDA finds problems during an inspection, they
can issue a formal document listing those problems,
right? What's that called? And what should a
company do if they get one? That's the FDA form
483, sometimes just called a 483. They give it
to the company at the end of the inspection if
the investigator saw anything that might be breaking
the rules. The best thing for the company to
do is respond in writing and do it promptly.
They should address each observation in the 483
and explain how they're going to fix it and make
sure it doesn't happen again. That's called corrective
and preventative action or CTA. And the FDA,
they categorize the results of these inspections.
What are those categories? What do they mean?
There are three main ones. First is NAI, no action
indicated. That's the best outcome. It means
they didn't find any major problems. Then there's
VAI, voluntary action indicated. That means they
found some problems, but they're not going to
take official action right away as long as the
company fixes the problems on their own. And
the most serious one is OAI, official action
indicated. That means they found some serious
GMP violations, and it's very likely the FDA
will take further action. Most companies respond
to a 483 within 15 business days. But if you
get an OAI classification, that's a big red flag.
It means the FDA is worried about your compliance,
and you can expect more scrutiny and probably
more instructions. And what are some of the things
the FDA can do if a company isn't following the
rules? What kind of actions can they take? Oh,
they have a whole toolbox of enforcement actions.
They can issue warning letters. Those are official
warnings detailing the violations and demanding
that the company fix them. And those warning
letters, they're public. Everyone can see them
on the FDA website. For foreign facilities that
aren't meeting GMP standards, they can issue
import alerts, basically blocking their products
from coming into the US. And if it's really serious,
they can do things like issue consent decrees.
Those are legal agreements with the company.
They can go to court and get an injunction to
stop the company from doing whatever they're
doing wrong. They can seize drug products. And
they can issue administrative detention orders,
which basically freezes those products in place.
And to wrap things up, we wanted to touch on
some of the newer, more forward -thinking approaches
to quality in the pharmaceutical industry, specifically
quality by design and risk management. Quality
by design, or QBD, that's a big one these days.
What's the main idea behind it? It's about changing
how we approach making drugs. Instead of just
testing the product at the end to see if it's
good, QBD is about building quality into the
entire process from the start. You really have
to understand what you want the final product
to be like, and you have to understand all the
factors that can affect that. So QBD is about
identifying those factors and controlling them
so that you consistently produce a high quality
product. And how does risk management fit into
all of this? Risk management, that's another
critical piece of GMP. It's about being proactive,
thinking ahead. First, you do a risk assessment.
You identify potential problems, you figure out
how likely they are to happen and how bad they
would be, and you evaluate the overall risk.
Then you move to risk control, where you develop
strategies to either reduce the risk or accept
it. And good risk management also involves communication.
Everyone who needs to know about the risks has
to be informed. And you have to review the whole
process regularly to make sure it's still working.
The goal is to use a science -based approach,
with patient safety and product quality always
being the top priority. The amount of effort
you put into managing a risk should depend on
how serious that risk is. And companies often
use tools like FMEA, failure mode, and effects
analysis to help them identify potential problems
and take steps to prevent those problems before
they affect the product. or hurt anyone. So as
we wrap up this deep dive, it's clear that making
sure drugs are safe and effective in the U .S.
clinical trial system is a huge complex undertaking.
We've come a long way from the early days when
things were much less regulated. Now we have
this intricate web of CGCP, GMP, and GDP all
working together with everything carefully controlled
and monitored. We talked about how important
documentation is, the need for good lab controls
and testing methods, the careful handling of
materials and equipment, the strict rules about
record and managing batches, the role of the
FDA in inspections and enforcement, and the increasing
use of modern approaches like quality by design
and risk management. And for our listeners, understanding
these regulations, it really gives you a glimpse
behind the curtain. You see all the work that
goes into making sure the medicines we take are
safe and effective. It's true. When you see all
the details, all the connections, it really makes
you appreciate just how complicated it is to
bring a new drug to market safely. It makes it
think, doesn't it? And maybe now knowing more
about CGCP and GMP, you'll look at clinical trial
results and drug information differently. It
gives you a whole new perspective.